INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 179 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2016. The put-call ratio across all filers is 0.65 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $8,056,000 | -30.7% | 74,150 | +5.0% | 0.89% | -21.8% |
| Q3 2016 | $11,628,000 | +49.1% | 70,651 | +29.3% | 1.14% | +41.7% |
| Q2 2016 | $7,798,000 | -75.3% | 54,651 | -77.7% | 0.80% | -47.2% |
| Q1 2016 | $31,533,000 | -4.1% | 245,447 | +11.5% | 1.52% | +8.9% |
| Q4 2015 | $32,864,000 | -9.8% | 220,047 | +0.2% | 1.40% | -16.1% |
| Q3 2015 | $36,431,000 | -15.0% | 219,647 | +23.6% | 1.67% | -6.7% |
| Q2 2015 | $42,880,000 | -7.8% | 177,647 | +7.7% | 1.79% | +1.3% |
| Q1 2015 | $46,518,000 | +64.0% | 164,947 | -9.3% | 1.77% | +38.8% |
| Q4 2014 | $28,368,000 | +53.9% | 181,847 | +133.5% | 1.27% | +63.9% |
| Q3 2014 | $18,436,000 | +5.3% | 77,893 | +5.3% | 0.78% | +4.6% |
| Q2 2014 | $17,509,000 | -28.7% | 73,993 | -0.7% | 0.74% | -26.6% |
| Q1 2014 | $24,567,000 | – | 74,493 | – | 1.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 640,688 | $9,514,000 | 1.49% |
| CM Management, LLC | 45,000 | $668,000 | 0.50% |
| EULAV Asset Management | 660,000 | $9,801,000 | 0.26% |
| DLD Asset Management, LP | 225,200 | $3,346,000 | 0.24% |
| Virtus ETF Advisers LLC | 21,387 | $318,000 | 0.14% |
| GSA CAPITAL PARTNERS LLP | 79,145 | $1,175,000 | 0.12% |
| Hennion & Walsh Asset Management, Inc. | 136,720 | $2,030,000 | 0.11% |
| ALTRINSIC GLOBAL ADVISORS LLC | 168,800 | $2,507,000 | 0.08% |
| Inspire Investing, LLC | 31,868 | $473,000 | 0.06% |
| DUALITY ADVISERS, LP | 51,196 | $760,000 | 0.06% |